89zr-dfo-n-suc-f8scfv
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2024 (NCT06645808)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Chondrosarcoma · Early Phase 1
- Colonic Neoplasms · Early Phase 1
- Colorectal Neoplasms · Early Phase 1
- Esophageal Neoplasms · Early Phase 1
- Glioblastoma · Early Phase 1
- Lung Neoplasms · Early Phase 1
- Neoplasms · Early Phase 1
- Osteosarcoma · Early Phase 1
- Pancreatic Neoplasms · Early Phase 1
- Squamous Cell Carcinoma of Head and Neck · Early Phase 1
- Stomach Neoplasms · Early Phase 1
- Urinary Bladder Neoplasms · Early Phase 1
Mechanism of action
- Citrate synthase, mitochondrialRadiopharmaceutical
CS radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06645808 | Early Phase 1 (Phase 1) | Nov 30, 2024 | TRACER, Var2 Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TRACER | For profit | 1 | 0 | 1 | 2024 |
| Var2 Pharmaceuticals | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1